Fresenius Kabi launches Simplist in prefilled syringe
Fresenius Kabi is offering Simplist palonosetron hydrochloride injection in in a 0.25 mg per 5 mL single dose ready-to-administer prefilled syringe.
This is the first and only FDA-approved prefilled delivery system for this medication, according to the company.
“The availability of Palonosetron Hydrochloride in a prefilled syringe is an important new option for clinicians treating people with cancer. Fresenius Kabi is pleased to be the first company to offer this medication in a ready-to-administer syringe,” Fresenius Kabi USA president and CEO John Ducker said in a statement. “Ready-to-administer delivery systems like this are designed to help improve patient safety and streamline drug preparation. We are pleased to continue to expand our Simplist portfolio to meet the needs of clinicians and the patients they treat.”
Palonosetron hydrochloride (HCl) injection is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses; and highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses.
Palonosetron HCl injection is indicated in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.
This is the first and only FDA-approved prefilled delivery system for this medication, according to the company.
“The availability of Palonosetron Hydrochloride in a prefilled syringe is an important new option for clinicians treating people with cancer. Fresenius Kabi is pleased to be the first company to offer this medication in a ready-to-administer syringe,” Fresenius Kabi USA president and CEO John Ducker said in a statement. “Ready-to-administer delivery systems like this are designed to help improve patient safety and streamline drug preparation. We are pleased to continue to expand our Simplist portfolio to meet the needs of clinicians and the patients they treat.”
Palonosetron hydrochloride (HCl) injection is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses; and highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses.
Palonosetron HCl injection is indicated in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.